Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 55/100

Failure Rate

16.7%

1 terminated/withdrawn out of 6 trials

Success Rate

80.0%

-6.5% vs industry average

Late-Stage Pipeline

83%

5 trials in Phase 3/4

Results Transparency

25%

1 of 4 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 4

3(50.0%)

Phase 3

2(33.3%)

N/A

1(16.7%)

6Total

Phase 4(3)

Phase 3(2)

N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT00852371Phase 3Completed

Intermittent Preventive Treatment of Malaria in Schoolchildren

Role: collaborator

NCT01184911Phase 4Withdrawn

Sulphadoxine-Pyrimethamine for Intermittent Preventive Treatment of Malaria in Pregnancy in Uganda

Role: collaborator

NCT00393679Phase 3Completed

Evaluation of 4 Artemisinin-based Combinations for Treating Uncomplicated Malaria in African Children

Role: collaborator

NCT01024426Phase 4Completed

Impact of Enhanced Health Facility Care in Uganda

Role: lead

NCT00716599Not ApplicableCompleted

Training in Fever Case Management With Rapid Diagnostic Tests (RDTs) for Malaria in Uganda

Role: collaborator

NCT00540202Phase 4Unknown

Effectiveness of Oral Quinine and Artemether-Lumefantrine in the Treatment of Uncomplicated Malaria in Ugandan Children

Role: collaborator

All 6 trials loaded